Quoin Pharmaceuticals (QNRX) Projected to Post Earnings on Thursday

Quoin Pharmaceuticals (NASDAQ:QNRX) will likely be posting its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Quoin Pharmaceuticals to post earnings of ($6.42) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 17, 2026 at 4:00 PM ET.

Quoin Pharmaceuticals Stock Down 2.8%

QNRX opened at $8.43 on Tuesday. The firm’s 50 day moving average is $9.76 and its 200-day moving average is $11.10. Quoin Pharmaceuticals has a 52-week low of $5.01 and a 52-week high of $41.80. The firm has a market capitalization of $7.08 million, a P/E ratio of -0.27 and a beta of 1.59.

Hedge Funds Weigh In On Quoin Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Ikarian Capital LLC purchased a new position in shares of Quoin Pharmaceuticals during the 4th quarter valued at approximately $3,052,000. Millennium Management LLC bought a new stake in shares of Quoin Pharmaceuticals in the fourth quarter worth $1,080,000. SummitTX Capital L.P. bought a new stake in shares of Quoin Pharmaceuticals in the fourth quarter worth $935,000. Boothbay Fund Management LLC acquired a new stake in Quoin Pharmaceuticals in the fourth quarter valued at $863,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Quoin Pharmaceuticals in the fourth quarter valued at $840,000. 8.63% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a report on Monday, December 22nd. Wall Street Zen upgraded shares of Quoin Pharmaceuticals to a “sell” rating in a report on Saturday, November 15th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Quoin Pharmaceuticals currently has a consensus rating of “Sell”.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.